1. Introduction {#sec1}
===============

Schizophrenia is a heterogeneous disorder not characterized by a single gene or possibly even a single biological pathway and likely belongs within a "spectrum of psychosis" ([@bib114]). The existence of a continuum of psychiatric illness encompassing disorders displaying psychotic symptoms, such as schizophrenia and bipolar disorder, could manifest from altered gene expression, controlled at both transcriptional and post-transcriptional levels. Gene expression profiling may be useful for addressing the issue of heterogeneity by identifying genes related to the underlying biology of schizophrenia.

Gene expression studies have been conducted in several brain regions using post-mortem tissue (see [@bib98] for a recent review), but large sample sizes of post-mortem brain tissue are difficult to collect and gene expression profiling in brain tissue is impractical in living patients. Alternatively, the investigation of gene expression in peripheral blood mononuclear cells (PBMCs) that are easily obtained, offer the possibility of longitudinal follow-up, ensure excellent RNA quality and show a considerable degree of heritability and stability in gene expression levels ([@bib68]) is a more feasible approach. Indeed, brain expressed genes are expressed in PBMCs and some show co-expression or similar expression levels in the same individuals, supporting their use as a surrogate tissue for gene expression profiling in schizophrenia ([@bib10]; [@bib33]; [@bib57]; [@bib89]; [@bib112]). In this regard, other groups have sought to identify blood-based expression profiles or develop panels of genes in small cohorts which may be useful for identifying functionally significant genetic and epigenetic changes in individuals with schizophrenia compared to healthy controls or even other related psychiatric disorders ([@bib48]; [@bib63]; [@bib71]; [@bib113]; [@bib115]).

Gene expression profiling in PBMCs could also be used to identify functionally relevant pathways in schizophrenia as the lymphocyte constituents may act as a point of communication between the immune and nervous systems ([@bib33]; [@bib112]). These cells have been shown to express a number of brain associated proteins including receptors for brain derived neurotrophic factor (*BDNF*), glucocorticoids, catecholamines, serotonin, dopamine and acetylcholine, and conversely many neurons express receptors for signaling molecules of the immune system (e.g. cytokines) ([@bib36]; [@bib47]; [@bib67]; [@bib76]). That there may be an immunological link to the pathophysiology of schizophrenia is not a new concept. Linkage and GWAS support an association of a broad section of markers in the major histocompatability complex (MHC) region at 6p21.33 with schizophrenia ([@bib16]; [@bib55]; [@bib56]; [@bib81]; [@bib87]; [@bib102]; [@bib108]) and other reports suggest this locus is biologically relevant to schizophrenia ([@bib51]; [@bib104]; [@bib109]). Immune-associated genes, genetic variants and haplotypes are also implicated in schizophrenia ([@bib52]; [@bib83]; [@bib84]). A recent study combining Gene Set Enrichment Analysis (GSEA) and hypergeometric analysis of GWAS data showed pathways relating to apoptosis, inflammation or immunity were over-represented in schizophrenia ([@bib41]).

Activation of the immune system is suggested by studies reporting altered levels of pro- and anti-inflammatory cytokines, acute phase proteins, complement components, antibodies and lymphocyte subset numbers, ratios, proliferation, activation and function in several tissue sources (serum, whole blood, cerebrospinal fluid (CSF)) from patients with schizophrenia ([@bib65]; [@bib70]; [@bib72]; [@bib86]). Moreover, signs of inflammation and activation or increased densities of microglia have been observed in post-mortem brains and CSF from patients with schizophrenia ([@bib23]; [@bib24]; [@bib74]; [@bib4]). A wealth of evidence suggests diverse environmental risk factors impacting on immune function may play a role in schizophrenia including maternal infection and birth in the peak infection seasons of Winter/Spring ([@bib11]; [@bib12]; [@bib69]; [@bib120]), maternal and neonatal deficiency in vitamin D which is critical for immunocompetency ([@bib66]; [@bib96]), malnutrition and psychological stress (reviewed in [@bib61]). Indeed, rodent models of maternal immune challenge results in schizophrenia-associated behavioral changes and cognitive deficits ([@bib79]; [@bib103]).

In support of an immunological manifestation of the disorder we recently identified a microRNA (miRNA) signature associated with immune function in PBMCs from individuals with schizophrenia ([@bib32]). Thus it is plausible that PBMCs reflect changes in the genome of patients with schizophrenia that define its character and etiology in those individuals. To further develop gene expression signatures that characterize the molecular background in individuals with schizophrenia we conducted gene or mRNA expression profiling in the largest PBMC cohort to date using the Australian Schizophrenia Research Bank (ASRB). The ASRB is a well characterized cohort of participants with a diagnosis of schizophrenia and carefully screened non-psychiatric controls ([@bib59]). Here we report differential expression of a large number of genes involved in the immune system.

2. Materials and methods {#sec2}
========================

2.1. Participant recruitment and clinical assessment protocol {#sec2.1}
-------------------------------------------------------------

This study utilized participants, the majority of whom identified as Caucasian, from the Australian Schizophrenia Research Bank (ASRB) and the Hunter DNA Bank (HDB) (describe previously by [@bib32] and [@bib59]). Ethics approval was obtained from the Hunter Area Health Services Human Research Ethics Committee and written informed consent obtained from all participants. In this study, the cohort consisted of 114 participants with a lifetime diagnosis of schizophrenia or schizoaffective disorder (cases) as diagnosed by the World Health Organization\'s ICD-10 criteria and 80 non-psychiatric controls. Demographic and clinical variables of the cohort are summarized in [Table 1](#tbl1){ref-type="table"} and detailed in [Supplementary Table 1](#appsec1){ref-type="sec"}. There was a significant difference in the mean age of cases and controls (mean age cases 42.3 years, controls 38.7 years, 2-tailed *t* test *p* = 0.0498) that is of a small magnitude. Similarly, there was a difference in mean age between schizophrenia and schizoaffective cases (mean age schizophrenia 41 years, mean age schizoaffective disorder 46 years, 2-tailed *t* test *p* = 0.03). This small difference in age in mature adults was considered to be unlikely to have significantly impacted upon gene expression. There was a significant difference in gender distribution of cases and controls with more males in the patient group compared to the controls (60% male cases, 42% male controls, 2-tailed Pearson Chi-square *p* = 0.013) although this is similar to the gender distribution in population samples. There was no difference in gender distribution between schizophrenia and schizoaffective cases (Pearson Chi-square *p* = 0.286).Table 1Summary of demographic and clinical characteristics of the participants.Demographic/clinical variableSummary statisticsNon-psychiatric control80Mean age (years)38.7Gender: M/F34/46Mean RQI9.0Cases[a](#tbl1fna){ref-type="table-fn"}114 Schizophrenia77 Schizoaffective disorder (manic type)16 Schizoaffective disorder (depressed type)13 Schizoaffective disorder (bipolar type)8Mean age (years)42.4Gender: M/F69/45Mean RQI9.1Mean age at onset of illness (years)23.96Family history schizophrenia (present/none/unknown)46/67/1Family history other psychosis (present/none/unknown)67/46/1Mean duration of illness (years)18.16[^2][^3]

2.2. Amplification and labeling of RNA {#sec2.2}
--------------------------------------

Whole blood was collected, followed by PBMC isolation, RNA extraction and integrity assessment as described previously ([@bib32]). The mean (SD) RQI for this cohort was 9.1 (0.8) and the RQIs were considered to be within the range of acceptable RNA quality according to the manufacturer\'s instructions (Bio-Rad Laboratories). Contaminants including phenol--chloroform, salts and genomic DNA were removed from total RNA using the RNeasy minikit (Qiagen, VIC, Australia) according to the manufacturer\'s instructions. Each RNA sample was then amplified, biotinylated and column purified prior to hybridization to the array using the TotalPrep Amplification kit (Ambion, ABI, CA, USA) according to the manufacturer\'s protocol.

2.3. Differential gene expression profiling {#sec2.3}
-------------------------------------------

Labeled RNA (750 ng) was hybridized to Illumina HT-12_V3 beadchips (∼48,000 probes) according to the manufacturer\'s protocol. Expression data underwent quality control analysis and background subtraction in GenomeStudio V3.0 (Illumina, CA, USA) and expression data was exported into R. Further quality control was conducted using the R with lumi packages ([www.bioconductor.org](http://www.bioconductor.org)) ([@bib26]), where the variance-stabilizing transformation (VST) ([@bib58]) was applied. An average of 9624 transcripts were detected for the cohort representing 20% of the total number of transcripts present on the array (detection *p* value \<0.05, before normalisation/background subtraction). Robust Quantile Normalization (RSN) was then applied to expression values for genes considered to be expressed (determined using the detection *p* value \<0.05), followed by differential expression analysis using a linear empirical Bayes model ([@bib105]). Significantly differentially expressed genes were identified after *p* value correction for multiple testing by the Benjamini and Hochberg method. Initial analysis indicated 307 transcripts were differentially expressed in schizophrenia compared to non-psychiatric controls ([Supplementary Table 2](#appsec1){ref-type="sec"}), which was refined to 164 altered transcripts after exclusion of genes with \<10% fold change and discontinued or poorly annotated NCBI Entrez Gene Database records.

2.4. Quantitative real-time reverse transcription PCR (Q-PCR) {#sec2.4}
-------------------------------------------------------------

Q-PCR validation of differentially expressed mRNA was performed on a subset of the cohort (83 participants: 48 schizophrenia or schizoaffective patients, 35 non-psychiatric controls) as described previously ([@bib92]). 10 genes were selected for Q-PCR validation based on strong differential expression of the array and/or biological significance. Both *MEF2D* (myocyte enhancer factor 2D) and *EIF2C2* (or argonaute 2; *AGO2*) (eukaryotic translation initiation factor 2C, 2) are implicated in miRNA biogenesis which we have previously shown to be altered in post-mortem brain ([@bib5]) as well as in PBMCs ([@bib32]). In addition, MEF2D was altered in neuroblast culture in response to retinoic acid-induced differentiation suggesting it may be involved in neuronal differentiation, a process that is biologically relevant to schizophrenia. Several genes were also chosen for their involvement in immune function: *EVL* (Enah/Vasp-like), *DEFA4* (defensin α4), *PI3* (peptidase inhibitor 3, skin-derived), *S100A12* (S100 calcium binding protein A12), *CCR7* (Chemokine (C--C motif) receptor 7), *CD6* molecule and *HMHA1* (histocompatibility (minor) HA-1). *VAMP5* (vesicle-associated membrane protein 5 (myobrevin)) was chosen, as it was one of the most strongly up-regulated genes. Primers were designed in Oligo Explorer V1.5 (Gene Link, NY, USA) (primer sequences are listed in [Supplementary Table 3](#appsec1){ref-type="sec"}). Relative mRNA expression was calculated as the ratio of the gene and the geometric mean of the most stable and efficient housekeeping genes hydroxymethylbilane synthase (*HMBS*) and 18S ribosomal RNA (*18S*). Outliers (expression \>3 standard deviations from the mean) were excluded from further analysis. Statistical significance of differential mRNA expression between schizophrenia and control groups was determined by Student\'s *t*-test (one-tailed *p* \< 0.05).

2.5. Effects of demographic variables on gene expression {#sec2.5}
--------------------------------------------------------

The effect of demographic variables was tested by correlation analysis where Pearson\'s Correlation was used for normally distributed data and Spearman Correlation was used for data that did not follow a normal distribution. Expression values from the microarray (for all 194 differentially expressed genes) and Q-PCR (validated genes) were tested for correlation with age. Additionally, for the validated genes, microarray and Q-PCR expression were analyzed for covariance with gender, RQI and diagnosis (schizophrenia compared to schizoaffective disorder) using a 2-tailed Mann--Whitney-*U* test and one-way ANOVA.

2.6. Bioinformatic functional analyses {#sec2.6}
--------------------------------------

To determine the most significant biological functions and pathways represented by the differentially expressed genes, a list of these genes and their corresponding fold changes were uploaded into Ingenuity Pathway Analysis (IPA) knowledge base v6.3 (Ingenuity Systems, USA, [www.ingenuity.com](http://www.ingenuity.com)). Of the 166 differentially expressed genes, 164 unique transcripts mapped to annotated gene IDs of which 140 were included in network analysis and 118 were eligible for functions annotation and pathways analysis. Functional Annotation Analysis of the differentially expressed genes was applied to determine the significant Biological Functions and Functions Annotation (*p* \< 0.05 after Benjamini--Hochberg correction for multiple testing) with at least 2 or more genes representing each annotation. Networks showing relationships and interactions between differentially expressed genes and others that functionally interact with them, were generated and ranked in terms of their relevance i.e. the number of participating genes, degree of connectivity and size relative to the total number of network eligible genes.

IPA also allowed the integration of mRNA expression data with miRNA expression data previously collected in an overlapping cohort in which 134 participants were common to both studies (61 controls and 73 cases) ([@bib32]). Expression data for the 83 miRNA that were identified as significantly differentially expressed in schizophrenia (FDR \<5) was uploaded to IPA where 60 had target prediction information. IPA identifies putative mRNA targets for the miRNA using experimentally validated interactions (TarBase and miRecords) as well as predicted miRNA--mRNA interactions (TargetScan Human Release 6.2; <http://www.targetscan.org/>; [@bib54]) and miRNA-related findings from the peer-reviewed literature. The putative miRNA:mRNA pairs were then filtered with respect to fold change to identify inverse miRNA:mRNA target pairs (where the expression of the miRNA is the opposite of it\'s mRNA target).

3. Results {#sec3}
==========

3.1. Gene expression profiling {#sec3.1}
------------------------------

mRNA expression was measured in 114 participants with schizophrenia or schizoaffective disorder (cases) compared to 80 non-psychiatric controls. A total of 164 genes displayed differential expression with changes ≥10% and *p* \< 0.05; 105 were down-regulated and 59 up-regulated in the cases compared to controls ([Fig. 1](#fig1){ref-type="fig"} , [Table 2](#tbl2){ref-type="table"} ). Ten genes were chosen for Q-PCR validation based on strong differential expression on the array and/or biological significance. Six genes were confirmed to have significant alterations in expression in the cases; myocyte enhancer factor 2D (*MEF2D*), eukaryotic translation initiation factor 2C, 2 (*EIF2C2*; or argonaute 2 (*AGO2*)) and Enah/Vasp-like (*EVL*) were down-regulated and defensin α4 (*DEFA4*), peptidase inhibitor 3, skin-derived (*PI3*) and S100 calcium binding protein A12 (*S100A12*) were up-regulated, validating the results of the microarray ([Fig. 2](#fig2){ref-type="fig"} and [Table 3](#tbl3){ref-type="table"} ). Validation of four additional genes was conducted. Chemokine (C--C motif) receptor 7 (*CCR7*; *p* = 0.054) and *CD6* molecule (*p* = 0.053), showed a strong trend toward down-regulation in the cases, whilst histocompatibility (minor) HA-1 (*HMHA1*; *p* = 0.089) and vesicle-associated membrane protein 5 (myobrevin) (*VAMP5*; *p* = 0.101) showed general trends toward down and up-regulation respectively ([Fig. 2](#fig2){ref-type="fig"}A and B), all of which were consistent with the microarray analysis. The fold changes detected by the microarray and Q-PCR were significantly correlated (Pearson *r* = 0.976, *p* \< 0.0001, data not shown) and in all but one instance, fold changes detected by Q-PCR were of greater magnitude compared to those detected on the microarray.Fig. 1Volcano plot of differentially expressed genes. A scatter-plot of the log odds (probability) against the log~2~ fold change in expression in PBMCs (schizophrenia/control). Genes with statistically significant differential expression in schizophrenia (Benjamini--Hochberg corrected *p* \< 0.05, fold change \>10% up or down-regulation) with current NCBI Entrez gene records are depicted in the upper quadrants; 105 genes down-regulated on the left (green) and 59 genes up-regulated on the right (red). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Table 2Differentially expressed genes in PBMCs in schizophrenia compared to non-psychiatric controls.Gene symbolGene nameChromosomal location*p* ValueFold change*Up-regulated*ASGR2Asialoglycoprotein receptor 217p0.00081.27RNASE3Ribonuclease, RNase A family, 314q24--q310.00491.36RNASE2Ribonuclease, RNase A family, 214q24--q310.00691.43ARPC4Actin related protein 2/3 complex, subunit 43p25.30.01061.31TCN1Transcobalamin I (vitamin B12 binding protein, R binder family)11q11--q120.01471.38SLPISecretory leukocyte peptidase inhibitor20q120.01921.3RPL34Ribosomal protein L344q250.01921.23ATP5SATP synthase, H+ transporting, mitochondrial Fo complex, subunit S (factor B)14q21.30.01921.13C9ORF16Chromosome 9 open reading frame 1616p11.20.02291.23VAMP5Vesicle-associated membrane protein 5 (myobrevin)2p11.20.02291.41RNASE6Ribonuclease, RNase A family, 614q11.20.02461.29CKLFChemokine-like factor16q210.02471.37EXOSC1Exosome component 110q240.02471.17WLSWntless homolog (drosophila)1p31.30.02471.13GTF2H5General transcription factor IIH, polypeptide 56q25.30.02551.18CYBRD1Cytochrome b reductase 12q31.10.02591.14HIBADH3-hydroxyisobutyrate dehydrogenase7p15.20.02771.15NTPCRNucleoside-triphosphatase, cancer-related1q42.20.02901.2CFPComplement factor properdinXp11.40.02961.32DYNLL1Dynein, light chain, LC8-type 112q24.230.02971.37CTSDCathepsin D11p15.50.03031.44PPPDE2PPPDE peptidase domain containing 222q13.20.03091.29ENTPD1Ectonucleoside triphosphate diphosphohydrolase 110q240.03091.19DEFA4Defensin, alpha 4, corticostatin8p23.10.03091.56NME1Non-metastatic cells 1, protein (NM23A) expressed in17q21.30.03141.22LSM1LSM1 homolog, U6 small nuclear RNA associated (*S. cerevisiae*)8p11.20.03141.37TFF3Trefoil factor 3 (intestinal)21q22.30.03221.11CSTBCystatin B (stefin B)21q22.30.03261.31RAB32RAB32, member RAS oncogene family6q24.30.03261.26MRPS18CMitochondrial ribosomal protein S18C4q21.230.03261.2CNPY2Canopy 2 homolog (zebrafish)12q150.03261.19UQCRBUbiquinol-cytochrome c reductase binding protein8q220.03311.12C18ORF10Chromosome 18 open reading frame 1018q12.20.03361.11DEFA1BDefensin, alpha 1B8p23.10.03391.73HIST1H2BKHistone cluster 1, H2bk6p21.330.03391.34AZU1Azurocidin 119p13.30.03481.31ACPPAcid phosphatase, prostate3q21--q230.03481.11RNF130Ring finger protein 1305q35.30.03541.31LGALS3Lectin, galactoside-binding, soluble, 314q22.30.03561.28RAB5CRAB5C, member RAS oncogene family17q21.20.03561.24HMGN2High mobility group nucleosomal binding domain 21p36.10.03561.21RPS4Y2Ribosomal protein S4, Y-linked 2Yq11.2230.03561.19S100A12S100 calcium binding protein A121q210.03571.7HBDHemoglobin, delta11p15.50.03571.58POLR2CPolymerase (RNA) II (DNA directed) polypeptide C, 33 kDa16q13--q210.03661.22LCN2Lipocalin 29q340.03921.47MS4A3Membrane-spanning 4-domains, subfamily A, member 3 (hematopoietic cell-specific)11q12.10.04021.16DBIDiazepam binding inhibitor (GABA receptor modulator, acyl-CoA binding protein)2q12--q210.04121.33C19ORF70Chromosome 19 open reading frame 7019p13.30.04181.33TM2D1TM2 domain containing 11p31.30.04401.13GMPR2Guanosine monophosphate reductase 214q120.04481.19CHMP3 (VPS24)Vacuolar protein sorting 24 homolog (*S. cerevisiae*)2p11.20.04531.1CDC42SE1CDC42 small effector 11q21.30.04541.18MRPS33Mitochondrial ribosomal protein S337q340.04541.16PI3Peptidase inhibitor 3, skin-derived20q13.120.04571.74PRDX5Peroxiredoxin 511q130.04601.32RPL23Ribosomal protein L2317q0.04781.5UBTD1Ubiquitin domain containing 110q24.20.04871.28RBX1Ring-box 1, E3 ubiquitin protein ligase22q13.20.04881.52*Down-regulated*TRRAPTransformation/transcription domain-associated protein7q21.2--q22.10.00030.73CCR7Chemokine (C--C motif) receptor 717q12--q21.20.00170.63EVLEnah/Vasp-like14q32.20.00490.64ZNF827Zinc finger protein 8274q31.220.00490.79BRAT1BRCA1-associated ATM activator 17p22.30.00490.83LEMD2LEM domain containing 26p21.310.00490.84C16ORF58Chromosome 16 open reading frame 5816p11.20.00670.76E4F1E4F transcription factor 116p13.30.00670.77RNF216Ring finger protein 2167p22.10.00670.82IL16Interleukin 16 (lymphocyte chemoattractant factor)15q26.30.00690.85HMHA1Histocompatibility (minor) HA-119p13.30.00970.71CHTOPChromatin target of PRMT11q21.30.01330.88IQSEC1IQ motif and Sec7 domain 13p25.20.01470.73CBLBCas-Br-M (murine) ecotropic retroviral transforming sequence b3q13.110.01470.79LRP5LLow density lipoprotein receptor-related protein 5-like22q11.230.01890.79SAFBScaffold attachment factor B19p13.3--p13.20.01920.71PLA2G4BPhospholipase A2, group IVB (cytosolic)15q11.2--q21.30.01920.71SGSM2Small G protein signaling modulator 217p13.30.01920.72SEC16ASEC16 homolog A (*S. cerevisiae*)9q34.30.01920.76LONP1Lon peptidase 1, mitochondrial19p13.20.01920.79SEC24CSEC24 family, member C (*S. cerevisiae*)10q22.20.01920.81MTMR14Myotubularin related protein 143p260.01920.84CD6CD6 molecule11q130.02050.64TYK2Tyrosine kinase 219p13.20.02110.66CBX6Chromobox homolog 622q13.10.02120.77RASAL3RAS protein activator like 319p13.120.02120.7STK10Serine/threonine kinase 105q35.10.02120.85FAM153BFamily with sequence similarity 153, member B5q35.20.02370.81C7ORF54Chromosome 7 open reading frame 547q310.02370.84CLUAP1Clusterin associated protein 116p13.30.02410.77BTBD11BTB (POZ) domain containing 1112q23.30.02410.8P2RY11Purinergic receptor P2Y, G-protein coupled, 1119p13.20.02410.84TJAP1Tight junction associated protein 1 (peripheral)6p21.10.02460.77ITPR3Inositol 1,4,5-trisphosphate receptor, type 36p210.02470.72TMEM175Transmembrane protein 1754p16.30.02470.76TGFBRAP1Transforming growth factor, beta receptor associated protein 12q12.10.02470.79SURF6Surfeit 69q34.20.02470.82NOP2NOP2 nucleolar protein homolog (yeast)12p130.02470.82PMPCAPeptidase (mitochondrial processing) alpha9q34.30.02470.83CTC1CTS telomere maintenance complex component 117p13.10.02470.83ZNF212Zinc finger protein 2127q36.10.02470.85ASXL1Additional sex combs like 1 (drosophila)20q11.10.02470.86CDK12Cyclin-dependent kinase 1217q120.02470.88MEF2DMyocyte enhancer factor 2D1q12--q230.02590.71COX19COX19 cytochrome c oxidase assembly homolog (*S. cerevisiae*)7p22.30.02900.77UBN1Ubinuclein 116p13.30.02950.76SNX29Sorting nexin 2916p13.13--p13.120.02960.73REC8REC8 homolog (yeast)14q11.2--q120.02970.8RHBDF2Rhomboid 5 homolog 2 (drosophila)17q25.10.02970.83MOV10Mov10, moloney leukemia virus 10, homolog (mouse)1p13.20.02970.83QSOX2Quiescin Q6 sulfhydryl oxidase 29q34.30.02970.84URGCPUpregulator of cell proliferation7p130.02970.88C19ORF6Chromosome 19 open reading frame 619p13.30.02970.78NAT10N-acetyltransferase 10 (GCN5-related)11p130.02970.74YY1AP1YY1 associated protein 11q220.02970.86EIF2C2 (AGO2)Eukaryotic translation initiation factor 2C, 28q240.03030.72PPP1R3EProtein phosphatase 1, regulatory (inhibitor) subunit 3E14q11.20.03040.88INTS1Integrator complex subunit 17p22.30.03090.8ISYNA1Inositol-3-phosphate synthase 119p13.110.03090.9ANP32A-IT1ANP32A intronic transcript 1 (non-protein coding)15q230.03090.89FCGBPFc fragment of IgG binding protein19q13.10.03190.79SBF1SET binding factor 122q13.330.03190.82SPG7Spastic paraplegia 7 (pure and complicated autosomal recessive)16q24.30.03220.74EDC4Enhancer of mRNA decapping 416q22.10.03260.62REXO1REX1, RNA exonuclease 1 homolog (*S. cerevisiae*)19p13.30.03260.79METTL16Methyltransferase like 1617p13.30.03260.82C9ORF91Chromosome 9 open reading frame 919q320.03260.85ZSCAN18Zinc finger and SCAN domain containing 1819q13.430.03260.83CACNA1ICalcium channel, voltage-dependent, T type, alpha 1I subunit22q13.10.03260.85HIC2Hypermethylated in cancer 222q11.210.03260.87RASA3RAS p21 protein activator 313q340.03260.88BCL11BB-cell CLL/lymphoma 11B (zinc finger protein)14q32.20.03310.83HDCHistidine decarboxylase15q21--q220.03390.8TSHZ1Teashirt zinc finger homeobox 118q22.30.03390.84MED29Mediator complex subunit 2919q13.20.03390.87FBXO32F-box protein 328q24.130.03390.88LRWD1Leucine-rich repeats and WD repeat domain containing 17q22.10.03480.81SFMBT2Scm-like with four mbt domains 210p140.03480.82ATF5Activating transcription factor 519q13.30.03480.88TNPO2Transportin 219p13.20.03560.79CREBBPCREB binding protein16p13.30.03570.84CTRLChymotrypsin-like16q22.10.03600.83C17ORF63Chromosome 17 open reading frame 6317q11.20.03660.86ZNF672Zinc finger protein 6721q440.03670.8POM121POM121 membrane glycoprotein7q11.230.03670.88ULK1Unc-51-like kinase 1 (*C. elegans*)12q24.30.03700.76TELO2TEL2, telomere maintenance 2, homolog (*S. cerevisiae*)16p13.30.03700.86ZNF446Zinc finger protein 44619q13.430.03840.9ELP2Elongation protein 2 homolog (*S. cerevisiae*)18q12.20.04060.84ZNF746Zinc finger protein 7467q36.10.04160.75ZNF395Zinc finger protein 3958p21.10.04290.78TRABDTraB domain containing22q13.330.04350.72CCDC130Coiled-coil domain containing 13019p13.20.04360.76MAP7D1MAP7 domain containing 11p34.30.04530.76TNK2Tyrosine kinase, non-receptor, 23q290.04530.8ZNF828Zinc finger protein 82813q340.04530.8EIF2B5Eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82 kDa3q27.10.04540.89EML3Echinoderm microtubule associated protein like 311q12.30.04540.73ABCF1ATP-binding cassette, sub-family F (GCN20), member 16p21.330.04540.78CCNT1Cyclin T112q13.110.04540.89MYO9BMyosin IXB19p13.10.04570.85ZNF362Zinc finger protein 3621p35.10.04600.86ZSWIM4Zinc finger, SWIM-type containing 419p13.130.04600.88KIAA0182KIAA018216q24.10.04610.88DMAP1DNA methyltransferase 1 associated protein 11p340.04970.85[^4]Fig. 2**A** QPCR validation of differentially expressed genes. The expression of ten genes highlighted by the microarray was analyzed by QPCR. Bars indicate mean fold change + SEM for 83 participants: 48 schizophrenia or schizoaffective patients and 35 non-psychiatric controls. The control cohort is set at 1. Differential expression of EIF2C2, EVL, DEFA4, S100A12 (\**p* \< 0.05) and PI3 and MEF2D (\*\**p* \< 0.01) was validated, with a further two genes (CCR7 *p* = 0.054; CD6 *p* = 0.053) showing a non-significant trend in the same direction as the microarray data. **B** Fold changes and *p* values for each gene on the microarray and the QPCR (one tailed student\'s *t*-test) are shown.Table 3Top biological functions enriched for differentially expressed genes in schizophrenia using IPA (Benjamini--Hochberg corrected *p* value range).*p*-Value range\# Molecules***Diseases and disorders***Infectious disease7.02E-08--3.35E-0222Respiratory disease7.02E-08--3.35E-0212Inflammatory response3.52E-05--4.63E-0218Dermatological diseases and conditions1.13E-04--4.72E-0220Genetic disorder5.46E-04--4.98E-0224***Molecular and cellular functions***Antigen presentation3.52E-05--4.98E-028Cellular movement3.52E-05--4.98E-0214Cell--cell signaling and interaction7.13E-05--4.98E-0215RNA damage and repair9.34E-05--1.69E-023Cell death1.29E-04--4.98E-0215***Physiological system development and function***Hematological system development and function3.52E-05--4.98E-0210Immune cell trafficking3.52E-05--4.98E-028Tissue development2.94E-03--4.17E-026Cell-mediated immune response8.48E-03--4.98E-024Connective tissue development and function8.48E-03--4.98E-024

3.2. Effects of demographic variables on gene expression {#sec3.2}
--------------------------------------------------------

Neither microarray nor Q-PCR data for *MEF2D*, *EIF2C2* (*AGO2*), *EVL*, *PI3*, *S100A12* and *DEFA4* showed a correlation with age or RQI (microarray: 2 tailed Spearman *p* \> 0.086; Q-PCR: Pearson correlation, *p* \> 0.304). There was no difference in expression of these genes between males and females (2-tailed Mann--Whitney-*U* test *p* \> 0.154) with the exception of *DEFA4* where the expression was greater in males than females by microarray (2-tailed Mann--Whitney-*U* test, *p* = 0.001). Indeed, this up-regulation of *DEFA4* was significant in male cases compared to male controls but was also up-regulated in female cases compared to female controls (2-tailed Mann--Whitney-*U* test *p* = 0.003 and *p* = 0.004 respectively) and this trend was confirmed by the Q-PCR data (not shown). One-way ANOVA revealed no difference in expression between schizophrenia and schizoaffective cases with the exception of *PI3*, in which mean expression in schizophrenia was higher than schizoaffective disorder on the microarray (*p* = 0.013) that was not supported by the Q-PCR data (*p* = 0.485). There was a significant correlation between the expression of *CCR7* (microarray data) and age (Spearman *r* = −0.2792, two-tailed *p* = 0.0001).

3.3. Functional annotation and bioinformatic analysis {#sec3.3}
-----------------------------------------------------

The list of differentially expressed genes and fold changes was submitted for Ingenuity Pathways Analysis (IPA). This analysis revealed the strong presence of genes involved in various aspects of immune function with ∼37% of the total functional annotations categorized as being immune/inflammation-associated ([Fig. 3](#fig3){ref-type="fig"} ). Top ranked biological functions included Infectious Disease, Inflammatory Response, Antigen Presentation, Immune Cell Trafficking and Cell-mediated Immune Response ([Table 3](#tbl3){ref-type="table"}). Immune/Inflammation related Functional Annotations included Severe Acute Respiratory Syndrome, Chemotaxis/Recruitment of various immune cells, Replication of a Virus, Respiratory/Infectious Disorder, Antimicrobial Response, Inflammatory/Immune Response ([Table 4](#tbl4){ref-type="table"} ). The full Functional Annotation Analysis is provided in [Supplementary Table 4](#appsec1){ref-type="sec"}. IPA identifies molecular relationships of differentially expressed genes in the context of biological pathways and indicated an enrichment of differentially expressed Immune/Inflammation-related genes in top scoring networks and canonical pathways ([Supplementary Tables 5 and 6](#appsec1){ref-type="sec"}). Network 1, enriched with functions including Cell-to-Cell Signaling and Interaction, Infectious Disease and Respiratory Disease is illustrated in [Supplementary Fig. 1](#appsec1){ref-type="sec"}.Fig. 3Functional annotations of differentially expressed genes by category. Assortment of functional annotations by broad functional categories revealed over-representation of genes with immune and inflammation-related functions (∼37%) in the list of genes differentially expressed between schizophrenia and controls.Table 4Immune and inflammation related functions enriched with differentially expressed genes in schizophrenia using IPA (Benjamini--Hochberg corrected *p* value).CategoryFunctions annotation*p*-Value\# MoleculesGenesInfectious disease; respiratory diseaseSevere acute respiratory syndrome\<0.00110CCR7, DEFA1 (includes others), DEFA4, HIST1H2BJ/HIST1H2BK, LCN2, RAB32, RNASE2, S100A12, SLPI, TCN1Antigen presentation; cellular movement; hematological system development and function; immune cell trafficking; inflammatory responseChemotaxis of antigen presenting cells\<0.0016AZU1, CCR7, CKLF, DEFA1 (includes others), IL16, RNASE2Cell deathKilling of cells\<0.0016AZU1, CTSD, DEFA1 (includes others), LGALS3, PI3, SLPIAntigen presentation; cellular movement; hematological system development and function; immune cell trafficking; inflammatory responseChemotaxis of phagocytes\<0.0017AZU1, CCR7, CKLF, DEFA1 (includes others), IL16, RNASE2, SLPIInfection mechanismReplication of HIV0.001215CCNT1, DEFA1 (includes others), IL16, MOV10, S100A12Inflammatory responseInflammation of tissue0.00153AZU1, CTSD, SLPIAntigen presentation; cellular movement; hematological system development and function; immune cell trafficking; inflammatory responseChemotaxis of macrophages0.003193AZU1, CKLF, DEFA1 (includes others)Infection mechanismReplication of RNA virus0.0044310CCNT1, DEFA1 (includes others), DMAP1, EIF2C2, IL16, LONP1, MOV10, S100A12, SAFB, TNK2Inflammatory responseImmune response0.0045117ABCF1, AZU1, CCR7, CFP, CKLF, CTSD, DEFA1 (includes others), ENTPD1, IL16, IQSEC1, LCN2, PRDX5, RNASE2, RNF216, S100A12, SLPI, TYK2Infection mechanismReplication of HIV-10.004744CCNT1, DEFA1 (includes others), MOV10, S100A12Cellular movement; hematological system development and function; immune cell traffickingCell movement of leukocytes0.006128AZU1, CCR7, CKLF, DEFA1 (includes others), IL16, LGALS3, RNASE2, SLPIAntigen presentation; cellular movement; hematological system development and function; immune cell trafficking; inflammatory responseChemotaxis of dendritic cells0.007793CCR7, IL16, RNASE2Cellular movementChemotaxis of eukaryotic cells0.007848AZU1, CCR7, CKLF, DEFA1 (includes others), IL16, RNASE2, SLPI, TFF3Antimicrobial responseInhibition of HIV0.008922DEFA1 (includes others), SLPICellular movement; hematological system development and function; immune cell traffickingHoming of mononuclear leukocytes0.015AZU1, CCR7, CKLF, DEFA1 (includes others), IL16Inflammatory response; antimicrobial responseAntimicrobial response0.01074AZU1, CFP, RNF216, S100A12Cellular movement; hematological system development and function; immune cell traffickingHoming of lymphocytes0.01184CCR7, CKLF, DEFA1 (includes others), IL16Inflammatory responseInflammatory response0.01249ABCF1, AZU1, CCR7, CKLF, DEFA1 (includes others), IL16, PRDX5, RNASE2, SLPIInfection mechanismProduction of virus0.01253CREBBP, MOV10, ULK1Inflammatory responseInflammation0.01295AZU1, CTSD, ENTPD1, S100A12, SLPICellular movement; immune cell traffickingMigration of leukocytes0.01638AZU1, CCR7, CKLF, DEFA1 (includes others), IL16, LGALS3, RNASE2, SLPICellular movement; hematological system development and function; immune cell traffickingChemotaxis of leukocyte cell lines0.01882CCR7, DEFA1 (includes others)Inflammatory response; antimicrobial responseAntibacterial response of organism0.02332AZU1, CFPInfectious diseaseInfectious disorder0.025222ABCF1, ASGR2, CBLB, CCNT1, CCR7, DEFA1 (includes others), DEFA4, EIF2B5, ELP2, HIST1H2BJ/HIST1H2BK, IL16, LCN2, POLR2C, RAB32, RNASE2, RNASE3, RNF216, S100A12, SLPI, SPG7, TCN1, TYK2Cellular movement; hematological system development and function; immune cell trafficking; cell-mediated immune responseHoming of T lymphocytes0.02583CCR7, DEFA1 (includes others), IL16Cellular movement; hematological system development and function; immune cell traffickingCell rolling of leukocytes0.02822CCR7, LGALS3Cellular movement; immune cell traffickingMigration of antigen presenting cells0.02863CCR7, IL16, LGALS3Antigen presentation; cellular movement; hematological system development and function; immune cell trafficking; inflammatory response; lymphoid tissue structure and developmentChemotaxis of neutrophils0.03353AZU1, CKLF, SLPIImmunological disease; hematological diseaseHypereosinophilia0.03542RNASE2, RNASE3Cellular movement; hematological system development and function; immune cell trafficking; inflammatory responseChemotaxis of mononuclear leukocytes0.0384AZU1, CKLF, DEFA1 (includes others), IL16Cellular movement; hematological system development and function; immune cell traffickingCell movement of granulocytes0.04044AZU1, CKLF, LGALS3, SLPIInfection mechanismBinding of virus0.04312ASGR2, CCNT1Cellular movement; immune cell trafficking; inflammatory responseMigration of phagocytes0.04634CCR7, IL16, LGALS3, SLPICell-to-cell signaling and interactionRecruitment of cells0.04813CCR7, ENTPD1, SLPI

Comparison of the mRNA expression data with the previously described miRNA expression data ([@bib32]) revealed 102 miRNA:mRNA pairings (in all cases the miRNA was down-regulated while the mRNA was up-regulated), consisting of 42 unique miRNA targeting 37 unique mRNA ([Supplementary Table 7](#appsec1){ref-type="sec"}).

4. Discussion {#sec4}
=============

In this study, we conducted differential mRNA expression profiling in the largest cohort of patients with schizophrenia or schizoaffective disorder compared with non-psychiatric controls reported to date. This revealed 164 differentially expressed genes (≥10%) after correction for multiple testing, supported by Q-PCR analysis of gene expression. Bioinformatic analysis of differentially expressed genes indicated enrichment of immune/inflammation-related functions providing supporting evidence for immune dysfunction in schizophrenia.

Interestingly, when we considered up-regulated genes in this enriched group separately, the innate immune response in particular was featured. For example, Secretory Leukocyte Peptidase Inhibitor (*SLPI*) and Azurocidin 1 (*AZU1*) are chemotactic for cells of the innate immune system and modulate the inflammatory response ([@bib91]; [@bib107]; [@bib111]). Lipocalin 2 (*LCN2*) is up-regulated during inflammation and in the plasma of patients with mild cognitive impairment ([@bib15]), and is induced by *IL-1β*, a protein elevated in the CSF of first episode schizophrenia patients ([@bib17]; [@bib106]). Chemokine-like factor (*CKLF*), has roles in dendritic cell maturation ([@bib37]; [@bib43]; [@bib99]) and is chemotactic for immune cells and possibly has roles in brain development ([@bib37]; [@bib118]). Two α-defensin family members, *DEFA4* (Q-PCR validated) and *DEFA1β* were up-regulated, consistent with increased α-defensin protein levels in T cell lysates from treated and antipsychotic free schizophrenia patients ([@bib18]). Defensins (endogenous peptide antibiotics) are abundant in neutrophil granules, natural killer cells and T lymphocyte subsets and act as immunomodulatory factors regulating acute inflammation, phagocytosis, cell migration/maturation and cytokine secretion ([@bib45]; [@bib88]; [@bib97]). *DEFA4* inhibits synthesis of anti-inflammatory glucocorticoids known to have significant influence on developing synaptic structure and function in the adult brain ([@bib82]). Many α-defensin genes cluster at 8p23, near a schizophrenia linkage site ([@bib27]; [@bib110]) known to be a hot spot for copy number variation (CNV) in normal individuals ([@bib1]).

Alternatively, when we considered the down-regulated genes, we observed a more even distribution of genes with function in both innate and cell-mediated immunity. Indeed, Surfeit 6 (*SURF6*), a marker of lymphocyte activation for proliferation ([@bib75]) and Interleukin 16, a dendritic cell chemo-attractant and modulator of T cell activation and inflammation ([@bib19]; [@bib42]) were down-regulated in schizophrenia. *CCR7* controls memory T cell migration to sites of inflammation and stimulates dendritic cell maturation ([@bib22]; [@bib30]). Down-regulation of *CD6*, a gene involved in T-cell activation promoting their commitment to a Th1 subtype and enhancing their sensitivity to the pro-inflammatory *IL-2* ([@bib77]), might be expected to have anti-inflammatory consequences.

This immune-related gene expression signature is in agreement with other blood-based studies in schizophrenia. [@bib34] identified several down-regulated genes from the MHC region in PBMCs and we identified changes to *ABCF1*, *LEMD2*, *TJAP1*, *ITPR3* and *HIST1H2BK* that reside at or near this locus. Interestingly, the major histocompatibility complex, class II, DR beta 1 (*HLA-DRB1*) was also down-regulated in the prefrontal cortex ([@bib34]). Three genes up-regulated in our study and in Glatt\'s study include the Galectin family member lectin, galactoside-binding, soluble 3 (*LGALS3*), a negative regulator of T lymphocyte activation ([@bib119]); the antiprotease, antibacterial and possibly anti-inflammatory Peptidase inhibitor 3, skin-derived (*PI3*) ([@bib91]) and the pro-inflammatory S100 calcium binding protein A12, calgranulin C (*S100A12*) ([@bib34]). *S100A12* was also up-regulated in leukocytes obtained from discordant schizophrenic sibling pairs with known linkage to 5q ([@bib71]). Related S100 genes (*S1200A1* and *S100A6*) were also up-regulated in our post-mortem study of the superior temporal gyrus (STG) in schizophrenia ([@bib9]) and *S100A9* was up-regulated in whole blood from schizophrenia patients ([@bib115]).

Similarly, [@bib49] identified differentially expressed genes in whole blood associated with "high hallucination state" or "high delusion state" groups, with 'Inflammatory Response', 'IL-8 Signaling' and 'Chemokine Signalling' as well as 'IL-15 production' among the top Diseases/Disorders or canonical pathways ([@bib49]). [@bib113] reported up-regulated genes in whole blood from patients with schizophrenia using the supervised classifier Artificial Neural Networks that featured in Gene Ontology (GO) biological processes such as 'Inflammatory Response', 'Lymphocyte Homeostasis', 'Defense Response', 'Immune System Process', 'Cytokine Biosynthetic Process' and 'Cytokine Metabolic Process' ([@bib113]).

The immune-associated mRNA expression signature also agrees with genes predicted to be targeted by a cluster of differentially expressed miRNA identified in an overlapping cohort to this study at chr14q32 that have roles in a range of immune-related pathways such as 'T Cell Receptor Signaling', 'Chemokine Signaling', 'Natural Killer Cell-Mediated Cytotoxicity' and 'Cytokine--Cytokine Receptor Interaction' ([@bib32]). Down-regulation of *EVL* is interesting since it is a host gene for miR-342 ([@bib35]), a member of the down-regulated 14q32 miRNA cluster. *EVL* is involved in remodeling of the actin cytoskeleton which is essential for processes in the CNS (such as axon guidance) and in the immune system (interaction between T lymphocytes and antigen-presenting cells, phagocytosis and chemotaxis of immune cells) ([@bib46]). Down-regulation of *EIF2C2* (encoding the endonuclease argonaute 2; *AGO2*) which functions in small non-coding RNA mediated gene silencing ([@bib13]) is interesting considering that members of the 14q32 miRNA cluster down-regulated in the cases in this cohort ([@bib32]) were over-represented among miRNA that were down-regulated in dopaminergic neurons from the striatum of Ago2-deficient mice ([@bib93]). Members of this cluster also contain structural features associated with dicer-independent/Ago2-slicer activity-dependent processing ([@bib21]; [@bib31]; [@bib80]). This suggests that *EIF2C2* is especially important for 14q32 cluster biogenesis and may be related to their down-regulation in PBMCs in these cases ([@bib32]) and supports our previous observations of altered miRNA biogenesis in schizophrenia in the cortex ([@bib5]). Similarly, down-regulation of *MEF2D*, a calcium-activated transcription factor, may also provide a mechanism driving the schizophrenia-associated down-regulation of the 14q32 miRNA cluster observed in this cohort since this transcription factor was shown to be a positive regulator of some of these miRNA in rat neurons ([@bib29]). Moreover, MEF2s have been shown to regulate immune cells ([@bib3]; [@bib85]) and *MEF2D* has important roles in the brain in neuro-development, neuronal survival and synaptic plasticity ([@bib38]; [@bib50]; [@bib101]). In addition, we have previously reported up-regulation of *MEF2D* in response to retinoic acid-induced neuronal differentiation ([@bib6]). The distinct roles this transcription factor has in immune function and in the brain makes it an attractive candidate for future investigation.

To further investigate the relationship between mRNA expression and differentially expressed miRNA reported in the overlapping cases ([@bib32]), the expression data was integrated revealing 102 predicted inverse miRNA:mRNA target pairings (where the miRNA was down-regulated and would be expected to lead to de-repression of the expression of the target mRNA, which was up-regulated), suggesting that miRNA and post transcriptional gene silencing has a significant influence on schizophrenia-associated changes in gene expression and regulatory networks.

Could this schizophrenia-associated change in the expression of genes with immune function in PBMCs have implications for brain development or function? One possibility is that this peripheral immune-related expression signature could be reflective of immune-dysfunction that is also manifested in the brain and may be indicative of underlying neuropathology. Indeed, the peripheral expression signature we observed was consistent to some extent with gene expression in the CNS which also show aberrant expression of immune and inflammation-associated genes, proteins and pathways, suggestive of an immune component in schizophrenia ([@bib2]; [@bib28]; [@bib53]; [@bib62]; [@bib64]; [@bib73]; [@bib90]; [@bib95]).

Despite these connections, the biological significance of altered expression of genes associated with immune function in schizophrenia is unknown. Therefore it is difficult to determine whether the immune-related expression signature reflects abnormality central and specific to the underlying pathogenesis of schizophrenia or is an indirect consequence of its pathophysiology or co-morbid environmental factor(s). The immune-related signature could reflect the *state* of illness. [@bib78] report that differentially expressed genes in post mortem brain from schizophrenia subjects are involved in inflammation, stimulus-response and immune-related pathways and were more strongly associated with long-term chronic schizophrenia ([@bib78]). The immune-related expression signature in our cohort, perhaps more representative of chronic schizophrenia is consistent with this observation. The molecular basis of the disorder may change with duration of illness and therefore whether these immune signatures are persistent through exacerbation and remission requires longitudinal studies. Additionally, whether these changes can be detected at the onset of illness could be assessed using first-episode psychosis cohorts. Another possibility is that medications are contributing toward the immune-associated gene expression signature. Indeed, a number of antipsychotics and antidepressants have been shown to display immunosuppressive and anti-inflammatory effects ([@bib14]; [@bib25]; [@bib94]; [@bib116]). Nevertheless, the influence of antipsychotic medication on gene expression could not be determined due to the nature of this information being self-reported by the participants with schizophrenia rather than through medical records. Similarly, obesity could also foster a pro-inflammatory state and may be affecting gene expression. However, since measures of current weight status e.g. body mass index (BMI) or waist circumference were not available, this possibility could not be further investigated.

Alternatively, the immune-related expression pattern may be indicative of a generalized immune disturbance apparent in many psychiatric and neurological disorders. In support of this, immune-related changes or abnormalities have been identified in schizophrenia and bipolar disorder ([@bib8]; [@bib100]), depression ([@bib60]; [@bib117]), anxiety ([@bib40]) and Alzheimer\'s disease ([@bib20]; [@bib39]). This hints at some common elements and suggests the immune system is vitally important for the development and function of the brain.

In summary, we have conducted a large genome-wide survey of gene expression in PBMCs from individuals with schizophrenia and schizoaffective disorder and identified a significant over-representation of genes associated with the immune system. While this has immediate functional implications for the relationship between the brain and the immune system, it may also be reflecting genetic, environmental or developmentally significant insults that are relevant to the pathogenesis of the disorder ([@bib7]; [@bib44]). In other words the immune expression signature in blood may be a residual image of this disturbance and provide insight into the etiopathogenesis of schizophrenia.
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[^1]: On behalf of the Australian Schizophrenia Research Bank.

[^2]: M -- male; F -- female; RQI -- RNA quality indicator.

[^3]: ICD-10 diagnosed schizophrenia or schizoaffective disorder (depressed, bipolar or manic subtype); family history other psychosis -- reports any other psychiatric mental illness in any first or second degree relative.

[^4]: Gene symbols for significantly up-regulated (*n* = 59) and down-regulated (*n* = 105) genes are shown (*p* value represents the corrected *p* value, after Benjamini--Hochberg multiple testing correction \<0.05).
